Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28864147 | 0.83 | EPHX2 (0.44) | KMT2AEPHX2FABP7FABP5CYP2C19 | |
| SCHEMBL119410 | 0.82 | KMT2A (0.49) | OPRD1OPRK1KMT2AOPRM1EPHX2 | |
| SCHEMBL4873237 | 0.81 | HSD11B1 (0.43) | OPRD1OPRK1KMT2AOPRM1FABP7 | |
| SCHEMBL16004761 | 0.80 | POLB (0.46) | KMT2AEPHX2FABP7FABP5 | |
| SCHEMBL22397770 | 0.80 | POLB (0.52) | KMT2AEPHX2FABP7FABP5SMN1; SMN2 | |
| SCHEMBL13327274 | 0.80 | POLB (0.52) | KMT2AEPHX2FABP7FABP5SMN1; SMN2 | |
| SCHEMBL25968740 | 0.79 | EPHX2 (0.43) | OPRD1KMT2AEPHX2FABP7FABP5 | |
| SCHEMBL2348837 | 0.79 | KMT2A (0.47) | KMT2AEPHX2FABP7FABP5CYP2C19 | |
| SCHEMBL7449064 | 0.79 | FABP5 (0.43) | KMT2AEPHX2FABP7FABP5SMN1; SMN2 | |
| SCHEMBL27143217 | 0.78 | KMT2A (0.43) | KMT2AEPHX2FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822548-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7825265-B2 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2008033894-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007056500-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | GPER1, ESR1, ESR2 | OPRD1 1667/4885OPRK1 657/4885KMT2A 1328/4885 |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESR2, ESR1, GPER1 | OPRD1 353/4885OPRK1 172/4885KMT2A 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.